Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 40 of the 54 sources its claims cite were checked for support.
Abstract
Basic and clinical studies demonstrate that depression is associated with reduced size of brain regions that regulate mood and cognition, including the prefrontal cortex and the hippocampus, and decreased neuronal synapses in these areas. Antidepressants can block or reverse these neuronal deficits, although typical antidepressants have limited efficacy and delayed response times of weeks to months. A notable recent discovery shows that ketamine, a N -methyl- d -aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants. Basic studies show that ketamine rapidly induces synaptogenesis and reverses the synaptic deficits caused by chronic stress. These findings highlight the central importance of homeostatic control of mood circuit connections and form the basis of a synaptogenic hypothesis of depression and treatment response.
Overview
CoChat Summary
TL;DR
The paper proposes a synaptogenic hypothesis of depression: stress and depression cause synaptic loss and neuronal atrophy in mood-related circuits, while rapid-acting ketamine reverses these deficits through glutamate burst, BDNF, mTOR, and synaptogenesis. It contrasts slow typical antidepressants with ketamine and highlights new therapeutic targets.
Key findings
- Depression is associated with decreased volume of cortical and limbic regions such as the prefrontal cortex (PFC) and hippocampus, and postmortem studies report decreased synapse number in the dorsolateral PFC, reduced pyramidal neuron size but not number, decreased GABAergic interneurons and glia, and altered GABA/glutamate cycling.
- Chronic stress in rodents reduces apical dendrite length and branching and decreases spine synapse number and function in layer V pyramidal neurons of the medial PFC; atrophy is observed after as little as 1 week of restraint stress (20 to 30 min per day), and chronic stress also decreases adult hippocampal neurogenesis and medial PFC glia.
- Ketamine produces rapid antidepressant responses within hours in treatment-resistant depressed patients, with effects sustained for 7 to 10 days; in rodents it rapidly induces synaptogenesis, reverses spine density deficits and anhedonia/anxiety caused by 3 weeks of chronic stress, and requires mTOR signaling, BDNF, Arc, and GSK3 inhibition.
- Typical antidepressants such as SSRIs take weeks to months to produce therapeutic response and leave more than one-third of depressed individuals resistant; they increase neurotrophic factor expression and plasticity slowly, whereas ketamine more profoundly affects fast excitatory glutamate transmission, BDNF release, and synaptogenesis.
Methods
- Review/perspective article synthesizing basic and clinical literature; no new primary data are reported.
- Evidence reviewed includes human brain-imaging and postmortem MDD studies, rodent chronic stress models (e.g., chronic unpredictable stress, restraint stress), and pharmacological studies of typical antidepressants and ketamine.
- Narrative synthesis comparing mechanisms of typical antidepressants and ketamine and proposing a synaptogenic hypothesis; no systematic review or meta-analysis is described.
Limitations
- Stated in the paper: MDD neurobiology remains poorly understood due to lack of biomarkers, relatively low heritability, and heterogeneity of precipitating factors; imaging provides connectivity information but not the integrity and efficiency of connections; postmortem neuronal morphology studies are hampered by poor fixation and tissue condition; preclinical interpretation is limited by available animal models, and additional human imaging is needed to confirm ketamine circuitry.
- Stated in the paper: ketamine’s psychotomimetic effects and abuse potential limit its development and use; clinical response to NR2B selective agents does not appear as rapid as ketamine, and further studies are needed; many molecular alterations in depression cannot always be distinguished from medication status because studies are not always sufficiently powered.
- Evident from the text: as a review, it does not provide a systematic search strategy, quality assessment, or primary quantitative synthesis; many mechanistic conclusions rely on rodent models and correlational human postmortem/imaging findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
27 Valid · 0 Not valid · 4 Not checked · 6 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Studies of neuronal morphology in human postmortem brain tissue have been hampered by poor fixation and tissue condition, but we recently reported that the number of synapses, determined by electron microscopy, is decreased in the dlPFC of depressed patients (16).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Neuronal Atrophy and Synaptic Loss in Depression
What the sources say
- Supportedcites [16] Kang HJ Nat. Med 2012 18 1413 22885997 PMC3491115 source
The paper reports a marked decrease in spine synapse number in the dorsolateral prefrontal cortex of subjects with major depressive disorder compared with controls. Its Electronic Microscopic Stereology methods describe counting those synapses in postmortem tissue using electron micrographs. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A notable recent discovery shows that ketamine, a N-methyl-D-aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants.”
- Also stated in: § Abstract · boosted
“Recent studies report what is arguably the most important discovery in half a century: the therapeutic agent ketamine that produces rapid (within hours) antidepressant actions in treatment-resistant depressed patients (4, 5).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Abstract
What the sources say
- Not checked — no full text of the sourcecites [4] Berman RM Biol. Psychiatry 2000 47 351 10686270 source
- Supportedcites [5] Zarate CA Jr Arch. Gen. Psychiatry 2006 63 856 16894061 source
The Comment section reports a robust antidepressant response to ketamine within hours in treatment-resistant subjects, with improvement over placebo significant from 110 minutes on clinician ratings and 40 minutes on self-ratings. It also identifies ketamine as an NMDA antagonist. Page numbers are not provided in the supplied passages. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · boosted
Every source the paper cites for this claim was checked and supports it.
In the paper
“Chronic unpredictable stress (CUS), a putative model of depression, results in behavioral abnormalities, including core symptoms of depression such as anhedonia (7).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Stress Causes Neuronal Atrophy and Decreases Synaptic Density
What the sources say
- Supportedcites [7] Li N Biol. Psychol 2011 69 754 source
The Conclusions describe CUS as a paradigm that results in anhedonia, a core symptom of depression. The Results report that CUS-exposed rats showed reduced sucrose preference, indicating anhedonia, and increased latency to feed in a novel environment, indicating another behavioral abnormality. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Partly supportedcites [6] Li N Science 2010 329 959 20724638 PMC3116441 sourceExperimental — accuracy not yet measured
The passage on behavioral tests (labeled Abstract; Fig. 3D–F) reports that local rapamycin infusion into the medial PFC completely blocked ketamine’s effects in the forced swim and novelty-suppressed feeding tests. Our copy does not report a dorsal-striatum infusion or establish that it failed to block those effects, so the regional comparison is unsupported. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, the synaptogenic actions of ketamine are blocked in mice with a knock-in of the BDNF Met allele that impairs BDNF mRNA transport to dendrites, as well as in conditional BDNF mutant mice (32, 49).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Not matchedcites [32] Liu R Biol. Psychol 2012 71 996
Its entry has no title and year that we can search by.
- Partly supportedcites [49] Autry AE Nature 2011 475 91 21677641 PMC3172695 sourceExperimental — accuracy not yet measured
The Abstract (page not provided) reports that ketamine did not produce antidepressant-like behavioural effects in inducible BDNF knockout mice. It does not report that ketamine’s synaptogenic effects were blocked in those mice, or describe BDNF Met knock-in mice or impaired dendritic mRNA transport. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Not matched
14 more claims · 10 with their cited sources checked
Create a free account to see all 37 claims and every source verdict.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While synaptic plasticity is a well-known key mechanism in learning and memory (Dayan and Cohen, 2011;Kandel, 2001), unequivocal studies suggest that dysfunction of synaptic plasticity with neuronal atrophy and cell death contribute to the pathophysiology of depression and therapeutic response could be associated with overcoming this deficit (Duman and Aghajanian, 2012;Krystal et al., 2013;Shakesb”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, synaptic dysfunctions with neuronal atrophy and reductions of glial and GABAergic interneurons in the dorsolateral prefrontal cortex (dlPFC) are found in post-mortem analyses of brains of depressive patients (and animal models of chronic unpredictable stress; Duman and Aghajanian, 2012; Underwood et al., 2012).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Broadly, positive valence system deficits are linked primarily to altered dopaminergic and/or opioid signaling within midbrain striatal circuits 94,101 , but may intersect with plasticity impairments and dysconnectivity of excitatory glutamatergic synapses in an overlapping prefrontal-mesolimbic circuit 5 to produce the full spectrum of affective biases seen in depression.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Such complex effects seem to ultimately result in increased neurogenesis and synaptogenesis, improved neuroplasticity, and normalization of stress-related neurodegeneration [77,78].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postmortem findings from these animal models consistently demostrate that stress induces synaptic dysfunction [5,6,135], including reductions in synaptic density, as measured by both quantification of synaptic structure and assessments of synaptic protein expression”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [6]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Self-citationNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Neurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606
Research works printed but not linked: 3
- Collinridge GL Peineau S Howland JG Wang YT Nat. Rev. Neurosci 2010 11 459 20559335
- 10.1016/0306-4522(95)00259-L · DOI · Paper page
- Machado-Vieira R Ibrahim L Henter ID Zarate CA Jr Pharmacol. Biochem. Behav 2012 100 678 21971560 PMC3253881 · DOI · Paper page
Cited by
Items 1,501–1,600 of 1,640
Hao, W., Ma, Q., Wang, L., Yuan, N., Gan, H. T., He, L., Li, X., Huang, J., & Chen, J. (2024) · Figshare · doi:10.6084/m9.figshare.26682964
Zeng, T., Li, J., Xie, L., Dong, Z., Chen, Q., Huang, S., Xie, S., Lai, Y., Li, J., Yan, W., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24180905
Zhang, Q., Liu, Z., Wang, Q., & Li, X. (2022) · Figshare · doi:10.6084/m9.figshare.19502423
Wang, S., Ishima, T., Zhang, J., Qu, Y., Chang, L., Pu, Y., Fujita, Y., Tan, Y., Wang, X., & Hashimoto, K. (2020) · Figshare · doi:10.6084/m9.figshare.12813504
Choe, S., Jeong, H., Choi, J., & Yu, S.-W. (2024) · Figshare · doi:10.6084/m9.figshare.25963139
Ju, L., Yang, J., Zhu, T., Liu, P., & Yang, J. (2022) · Figshare · doi:10.6084/m9.figshare.19367716
Qin, Z., Shi, D.-D., Li, W., Cheng, D., Zhang, Y.-D., Zhang, S., Tsoi, B., Zhao, J., Wang, Z., & Zhang, Z.-J. (2024) · Figshare · doi:10.6084/m9.figshare.26572114
Ju, L., Yang, J., Zhu, T., Liu, P., & Yang, J. (2022) · Figshare · doi:10.6084/m9.figshare.19367719
Chen, H., Hong, L., Tong, S., Li, M., Sun, S., Xu, Y., Liu, J., Feng, T., Li, Y., Lin, G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26581892
Hao, W., Ma, Q., Wang, L., Yuan, N., Gan, H. T., He, L., Li, X., Huang, J., & Chen, J. (2024) · Figshare · doi:10.6084/m9.figshare.26682961
Hao, W., Ma, Q., Wang, L., Yuan, N., Gan, H. T., He, L., Li, X., Huang, J., & Chen, J. (2024) · Figshare · doi:10.6084/m9.figshare.26682955
Hao, W., Ma, Q., Wang, L., Yuan, N., Gan, H. T., He, L., Li, X., Huang, J., & Chen, J. (2024) · Figshare · doi:10.6084/m9.figshare.26682958
Ju, L., Yang, J., Zhu, T., Liu, P., & Yang, J. (2022) · Figshare · doi:10.6084/m9.figshare.19367713
Kim, W.-S., Odkhuu, S., Setiani, A., Li, L., So, J.-Y., Nazir, S., & Chung, Y. (2025) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2025.112117
TRANSTORNO DEPRESSIVO MAIOR EM IDOSOS: DA NEUROBIOLOGIA À PRÁTICA CLÍNICA
del Corsso, C., Bertazo, M. M., Suzart, A. S., de Paula, M. F. G. M., Silva, L. A., da Silva, M. T. F. G., Ferreira, Í. D. C., Ribeiro, M. A., & Cardoso, R. (2026) · Revista Contemporânea · doi:10.56083/rcv6n1-014 · Cited by 2
Plant-Based Antidepressants: An Overview of Bioactive Compounds and Screening Strategies
Gupta, R., Kushwaha, N., & Kushwaha, S. K. S. (2026) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v16i1.7536
Tu, Y., Fu, Q., Li, Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.26.701905
Kosted, R., Waddell, A., Adolph, K., & Fonzo, G. A. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121350 · Cited by 1
Ketamine attenuates habenula activity in response to aversive outcomes during Pavlovian learningPreprint
Pulcu, E., Costi, S., Artiach-Hortelano, P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.08.704729
Guo, M., Fan, T., Li, Y., Yi, W., Wang, J., Hu, Y., Yan, F., Huang, Y., Gong, Y., Chen, C., et al. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106491 · Cited by 2
Vidhya Joth, N. (2024) · Cuestiones de Fisioterapia · doi:10.48047/en272v57
Rafało-Ulińska, A., Gąsior, Ł., Zaręba-Kozioł, M., Wodarczyk, J., Pukło, R., Haduch, A., Daniel, W. A., & Szewczyk, B. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111643
The Eph-ephrin system in neuropsychiatric and neurodevelopmental disorders
Bordignon, A., Manduca, J. D., & Perreault, M. L. (2026) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn-2025-0168 · Cited by 2
Jeong, S., Lee, A. Y., Chae, S., Kim, J., Jang, H., Moon, C., Lee, H., Lee, D. Y., Lee, M.-H., Kim, J. S., et al. (2026) · Korean Journal of Medicinal Crop Science · doi:10.7783/kjmcs.2026.34.1.12
Yang, Y., Fan, B., Zhi, T. T., Wu, Y., Wu, L., Xie, Z., Zhang, S., Mu, R. H., & Wu, X. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116465
Hou, Y., ZHANG, Y., Chao, H., Hui, S., & Meng, P. (2026) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2026.111821
Hippocampal REDD1 inhibition is critical for alleviating depressive-like behaviors
Xu, C., Liao, M.-X., Zhang, S.-Z., Shu, L.-X.-Y., Xu, P., Chen, Y.-A., Wang, M.-Q., Cheng, T., Yang, X., Xie, Y., et al. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01760-6
“However, its addictive effects and potential for abuse have restricted the broader application of ketamine in treating MDD [11].”
Živanović, A., Mitić, M., Lukić, I., Glavonic, E., Adžić, M., & Ivković, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062815 · Cited by 3
“Although chronic stress often reduces hippocampal BDNF [39–41], its direction and magnitude can vary with stress timing and duration, sometimes resulting in recovery or even upregulation [42].”
Atídio, J. P., Delfino, R. S., Garios, I. S., de Brito, C. S. G. F., Gerheim, Y. P., Vasconcelos, G. M. D. A. E., Piloto, R., Ferro, M. D., Júnior, R. O. P. D. S., Surjan, J. C., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121721
Epigenetic regulation of BDNF-TRKB signaling in the pathophysiology and treatment of mood disorders
Boulle, F. (2013) · theses.fr (ABES) · doi:10.70675/7796cc83z9f91z48c6zadb1zb6a90897b5d5
“Up to date, clinical and preclinical studies have revealed that depression could be linked to alterations in cortico-limbic structures controlling mood and emotions, including neuronal loss and synaptic dysfunction (Duman and Aghajanian, 2012).”
BackgroundMaltman, J. L., & González‐Maeso, J. (2026) · eLife · doi:10.7554/elife.110981
Le récepteur 3 de la neurotensine/Sortiline dans la régulation de l’état dépressif
Moréno, S. (2017) · theses.fr (ABES) · doi:10.70675/bd5432bcz3426z4e54z9081zd99b2eb3f712 · Cited by 1
Émotions et sommeil paradoxal : étude comportementale, fonctionnelle et anatomique chez la souris
Rosier, M. (2017) · theses.fr (ABES) · doi:10.70675/18fbbb85zbcdcz4c31zabe2zd1d91cdf4659 · Cited by 2
Rothärmel, M. (2019) · theses.fr (ABES) · doi:10.70675/e8883013z1f99z4729z9f22z3ebbd6f1586a · Cited by 2
Potentialisation de la réponse antidépressive par la lumière : étude préclinique
Delcourte, S. (2019) · theses.fr (ABES) · doi:10.70675/7468b6d3zbf12z4888z88afzc63efcc91723
Life Cycle and Circadian Rhythms in Central Resident Immunity and Neuropsychiatric Pathology
Lim, Z., Nguyen, H. L., Zeng, Y., Qu, Q., Le, Y., Sun, M., Wang, X., Zhu, H., Qian, Y., Saeed, S., et al. (2026) · Neuroscience Bulletin · doi:10.1007/s12264-026-01612-7 · Cited by 1
“This leads to Ca 2+ -mediated mitochondrial ROS production and prefrontal-hippocampal dendritic atrophy [120].”
de Oliveira, C. M. (2021) · theses.fr (ABES) · doi:10.70675/7291a4e5z9949z4fd4za27dze7f18385347b · Cited by 2
Esketamine ameliorates depression-like behavior in mice via modulation of the NRG1–ErbB4 pathway
Yu, H., Zhu, Y., Wang, J., He, Y., Li, H., Li, S., Wang, N., Chen, N., Chen, J., Song, H., et al. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1722336
Exploring the molecular determinants of behavioral changes induced by ketamine at the nanoscale
Uyttersprot, F. (2024) · theses.fr (ABES) · doi:10.70675/df438baaz92d0z488aza38cz4227b46c9acb
Dexamethasone-induced 3D cortical spheroid model of stress-related neuroplasticity impairment
Seo, M. K., Lee, J. G., Lee, J. A., Park, J. W., Kang, D.-K., Seog, D., Kim, M. H., Jeong, S., & Park, S. W. (2026) · Scientific Reports · doi:10.1038/s41598-026-47738-6
“the key mechanisms underlying the disorder 5–8 .”
Nasef, M. S., Abozeid, S., & Hassan, S. A. (2026) · Scientific Reports · doi:10.1038/s41598-026-44875-w
Yang, X. (2026) · Precision Medical Sciences · doi:10.1002/prm2.70033
Abdulla, Z. I., Garcia-Milian, R., Giahyue, E., Fertuzinhos, S., Collin, F., Wang, W., Lam, T. T., Nairn, A. C., & Picciotto, M. R. (2026) · eNeuro · doi:10.1523/eneuro.0030-26.2026
“ACh signaling has been implicated in synaptic plasticity (Picciotto et al., 2012), and depression has been proposed to be a disease of synaptic dysfunction, whereas several ef fi cacious antidepressants promote synaptogenesis (Duman and Aghajanian, 2012; Popoli et al., 2012).”
Ketamine Metabolites Promote Anxiolysis and Hydrocortisone Stress Buffering in Zebrafish
Kelly, J. R., Brasfield, L. S., Kelsey, A. H., & Seal, G. E. (2026) · Behavioural Brain Research · doi:10.1016/j.bbr.2026.116230
Wang, X.-L., & Serchov, T. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106700 · Cited by 3
Sureshkumar, P. V., S, R. H., Vadlamudi, S., & Sadasivan, U. (2026) · Cureus · doi:10.7759/cureus.107622
“Impaired BDNF signaling is a hallmark of depression and is associated with reduced synaptic plasticity and neuronal survival [6].”
Carmellini, P., Cuomo, A., Rescalli, M. B., Pinzi, M., Dourmas, A., & Fagiolini, A. M. (2026) · Pharmaceuticals · doi:10.3390/ph19050662 · Cited by 1
“In this perspective, monoamines act as modulators of neural tone and network stability, while glutamate orchestrates synaptic adaptability, dendritic remodeling, and circuit-level integration [13].”
InfluentialWu, S., Jiang, Y., Zhai, C., Li, P., Yang, H., Xu, C., Wang, Y., Liu, J.-G., & Zhang, L. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116727
Distinct therapeutic profiles of ketamine in treatment-resistant depression: an exploratory analysis
Liu, K.-W., Lin, W., Li, C., Bai, Y., Su, T., & Chen, M. (2026) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyag021
“34,35 While ketamine is known to promote rapidsynaptogenesis, 36 theneuroprogressivechangesassociatedwith high levels of treatment resistance may impose a ceiling on functional recovery achievable with a single infusion.”
Ma, Z.-J., Zou, T., Zhou, Y.-S., Li, X., Hu, Z., Liu, G.-X., Xia, L., & Chen, G.-H. (2026) · Discover Mental Health · doi:10.1007/s44192-026-00467-8 · Cited by 1
“For example, interventions like electro-convulsive therapy, which enhances astrocytic connectivity and potentially GDNF signaling, may preferentially benefit recurrent depression patients with low baseline CX26 and/or GDNF [43].”
Neuroprotective Effects of Carnosine Against Corticosterone‐Induced Depression and Memory Impairment
Elahi, M., Samad, N., Irfan, A., Manzoor, N., Ahmed, M. Z., Матеев, Е., & Jardan, Y. A. B. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.71837 · Cited by 1
“…cytokines (Frank et al. 2011; Munhoz et al. 2006), and the disruption of neurotransmitter systems such as glutamatergic, GABAergic, and monoaminergic neurotransmission, thereby impairing synaptic plasticity, mood regulation, and cognition (Duman and Aghajanian 2012; Mahar et al. 2014).”
Huan, G., Wang, S., Liu, Q., Jia, J., Yang, Y., & Jin, Z. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.111009
HitoraーImamura, N., Nishida, Y., Kawazoe, K., Ono, K., Kumamoto, H., Kurauchi, Y., & Katsuki, H. (2026) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2026.05.004
Mechanistic Action of Oxidative Stress in Depression
Singh, A., & Shukla, S. (2026) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-3-032-19837-2_8
Sunzeri, F. (2026) · Springer eBooks · doi:10.1007/978-3-032-14465-2_14
Takahashi, M., & Shelton, R. C. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2674645
“Chronic stress also induces dendritic atrophy and spine loss in medial PFC pyramidal neurons, weakening excitatory postsynaptic signaling and disrupting monoaminergic and hypocretin systems [19].”
Neurological Perspectives on Disability in Unipolar Depression
Israr, J., Alam, S., & Kumar, A. (2026) · SpringerBriefs in modern perspectives on disability research. · doi:10.1007/978-981-95-8955-5_2
Thulasingam, M., & Vellapandian, C. (2026) · Current Drug Therapy · doi:10.2174/0115748855435564251207185418
Wasolua, T. T., Bommersbach, T. J., McIntyre, R. S., & Rhee, T. G. (2026) · Research Square · doi:10.21203/rs.3.rs-9827580/v1
“93 However, key components of this model remain debated: mTOR activation has not been consistently replicated as essential for ketamine's antidepressant effects, including in a clinical study that found no association between mTOR signaling and treatment response.”
Rush, S., & Nasrallah, H. A. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2675008
“Together, these findings form the basis of the neurotrophic hypothesis of depression, which posits that impaired neurotrophic signaling, rather than monoamine deficiency alone, represents a core cellular pathology of major depressive disorder [8,12,13].”
InfluentialWang, J., Wang, S., Zhao, Z., Li, N., & Zhang, B. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-08230-7
“Similarly, the enrichment of syn- apse-and plasticity-related terms among PLS1 − genes may indicate that FNC alteration patterns are spatially related to gene-expression profiles involved in synaptic organization and neural plasticity [46, 47].”
Wang, Y., Wu, Z., & Pan, N. (2026) · Epileptic Disorders · doi:10.1002/epd2.70266
Chapter 1. Basic Principles of Transcranial Magnetic Stimulation
Lanocha, K. I., Bermudes, R. A., & Janicak, P. G. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894550671.lg01 · Cited by 1
Eldaweny, A. M., Yahia, S., Sayed, R. H., Abdelaziz, A. I., & El-sherbiny, I. M. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108583
Optimization and evaluation of a chronic variable stress model of depressive-like behaviors in mice
Du, L., Guo, Y., Fang, S., Zuo, W., Xie, X., Zeng, Y., Wang, Q., Kou, J., Hou, W., & Wang, M. (2026) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2026.110824
Liu, M., Wang, W., Zhang, Y., Yong, J., Jiang, Q., Sun, R., Xiao, H., Han, S., He, L., Yu, H., et al. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.122005
Sex Differences in Depression: Adult Cytogenesis as Potential Target for Precision Psychiatry
Rodrigues-Freitas, L., Pinto, L., & Canedo, T. (2026) · Cells · doi:10.3390/cells15121059 · Cited by 1
“In general, upon stress, the number of synapses is decreased in the hip-https pocampus and the prefrontal cortex [94].”
Zhang, L., Kong, X., Ma, Q., Hu, X., Cai, S., Wang, B., Zou, W., Bai, T., Zhang, M., Fan, L., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02638-3 · Cited by 2
“1j), which were considered to play essential roles in MDD 23 , our subsequent analyses focused on neurons.”
Persin, M. J., Julian, K. M., & Bennett, J. M. (2026) · Journal of Behavioral Medicine · doi:10.1007/s10865-026-00682-2
Berghmans, C., & Monciino, A. (2026) · L Évolution Psychiatrique · doi:10.1016/j.evopsy.2026.03.009
Gunawan, E., Lesmana, R., Gunawan, H., ROSDIANTO, A. M., Lubis, L., Pandia, V., & Purba, A. (2026) · F1000Research · doi:10.12688/f1000research.181861.1
Parks, A. C., Woodward, A. L., Vlisides‐Henry, R. D., Arden, K., Vando, L., Swain, J., & Lamichhane, B. (2026) · Journal of Medical Internet Research · doi:10.2196/92647 · Cited by 1
“Unlike traditional antidepressants, ketamine works by rapid synaptogenesis and glutamate modulation, both of which result in near-immediate relief [33].”
Ni, X., Zhou, S., He, X., Wu, K., Liang, G., Wang, A., & Xu, X. (2026) · Toxicology in Vitro · doi:10.1016/j.tiv.2026.106274
LIU, J., Yang, X.-Y., Wu, D., Chen, H., Li, S.-J., Li, X., Yang, J., & Gao, T. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108311
Akram, M. B., Sher, A., Fatima, A., Arif, A., Sareshwala, D. F., Nawaz, Z., & Khalil, U. (2026) · INNOVAPATH · doi:10.63501/54mphj57
“Alterations in NMDA receptor signaling and reduced brain-derived neurotrophic factor (BDNF) levels have been implicated in persistent depressive states (3,4).”
Gao, H., Ma, Y., Qian, R., Jin, T., Gu, B., Qiu, B., Ye, S., Huang, M., Wu, D. W., & Zhao, Z. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.06.016
Mrówczyńska, L., & Mrówczyński, W. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135881 · Cited by 1
“These include chronic psychological stress combined with prolonged exposure to glucocorticoids [48–51], sleep deprivation [52–55], oxidative stress resulting from mitochondrial dysfunction during periods of high energy demand, the excitotoxic activity of glutamate, hypoxia, ischemia, and various…”
Seo, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27136084 · Cited by 1
“…it does not adequately explain the delayed therapeutic onset of conventional agents, the substantial proportion of patients with treatment-resistant depression, or the rapid clinical effects observed after interventions targeting glutamatergic and excitability-related pathways [1–4].”
Zeng, X., Zhao, Y., Deng, B., Lu, Y., Yu, H., You, Q., & ZHAI, X. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179114
Bellanti, P. A., Lewis, J., Seifferth, B., & Adams, D. Z. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1867963 · Cited by 2
“Both agents exert antidepressant effects through NMDA receptor antagonism and downstream enhancement of synaptic plasticity (24).”
Khutwad, D. D., Otari, K. V., & Kale, A. Y. (2026) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3519
Murase, Y., Ogata, H., Shimamoto, Y., Funatsuki, T., Koshikawa, Y., Takekita, Y., Hashimoto, K., & Kato, M. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122231
Cheung, H. K., & Cheung, N. (2026) · Cureus · doi:10.7759/cureus.112492
“Ketamine-class work suggests that rapid behavioral effects may involve α -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-dependent downstream plasticity rather than NMDA blockade alone [6-9].”
Yao, Y.-Q., Zhi-yi, X., Guo, B., Wang, C., Hong, H., Chen, Z.-G., & Tang, S.-S. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01874-x · Cited by 1
“…has demonstrated that hippocampal neuroplasticity dysfunction, including impaired synaptic architecture and suppressed neurogenesis, is a central pathological hallmark of depression, and targeted modulation of neuroplasticity-associated signaling exerts robust antidepressant effects [31, 55].”
Cao, Z., Yuan, D., Qin, J., Wu, Y., Li, C., & 占归来 (2026) · Human Brain Mapping · doi:10.1002/hbm.70605
“Prior studies have suggested that both GABAergic and glutamatergic signaling play key roles in depression (Duman and Aghajanian 2012; Duman et al. 2016, 2019), providing broader biological context for MDD-related cortical changes.”
Urbanowicz, A., Zimny-Zając, A., Dróżdż, M., Agrawal, S., & Mazur, G. (2026) · BMC Public Health · doi:10.1186/s12889-026-28469-9 · Cited by 1
“…findings strongly support models of allostatic load [6], in which chronic stress leads to physiological and psychological dysregulation [27–29], and they are consistent with large-scale population evidence identifying psychological stress as a key driver of depression and diminished…”
Tu, Y., Fu, Q., Li, Y., Sun, C., Zhu, Y., Zeng, X., Qin, H., Zeng, X., Wang, Y., Qiu, S., et al. (2026) · NeuroSci · doi:10.3390/neurosci7040081
PM2.5 induced neurotoxicity and depression unveiling exposure risks and mechanistic insights
Ma, Z., & Yau, S. (2026) · iScience · doi:10.1016/j.isci.2026.116617 · Cited by 1
“128,129 PM 2.5 exposure may exert multifaceted detrimental effects on neurons, ranging from structural damage and synaptic dysfunction to neuroinflammation and genetic dysregulation.”
InfluentialWu, Q., Li, W., Luo, Z., Wang, C., Lan, X., Shen, J., Chen, Z. X., Pan, J., Liu, X., Zhu, H., et al. (2026) · BMC Psychiatry · doi:10.21203/rs.3.rs-10020524/v1
Younkin, J., Bansode, A. H., Saha, S., Paymode, A., Maltman, J. L., Jones, C. B., Silverman, J. M., Buzzi, B., Jaster, A. M., Fiorillo, M., et al. (2026) · Science Signaling · doi:10.1126/scisignal.adw6055 · Cited by 1
Klepacki, H., Ordak, M., Kowalczuk, K., Hermanowicz, J. M., & Waszkiewicz, N. (2026) · Antioxidants · doi:10.3390/antiox15070908
“The shared lower-expression direction of BDNF , VGF , EGR1 , NPTX2 , and SAT1 in the dlPFC supports the interpretation that MDD may be associated with reduced molecular capacity for adaptive plasticity and stress-related regulation [11,17,31].”
Zhang, F., Qian, J.-J., Chen, W., Zhu, B.-L., Jin, F., Shen, J.-Y., Jiang, B., Fan, H., & Zhao, H. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179170
Li, Y., Ding, Z., Wu, H., Chen, Y., Qin, J., Liang, J., & Fan, F. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111869
Sleep, anxiety, and depression: The bidirectional brain-behavior axis
Rao, J. K., Emani, L. S., Padhi, S., Sharafkhaneh, A., Nami, M., & Rao, K. S. J. (2026) · Progress in brain research · doi:10.1016/bs.pbr.2026.07.007
Lee, J. G., & Park, Y.-M. (2026) · Springer eBooks · doi:10.1007/978-981-92-1331-3_11
Metadata
- Authors
- Duman, R. S., & Aghajanian, G. K.
- Affiliations
- Yale University (US)
- Corresponding author
- Duman, Ronald S.
- ORCID
- Duman, Ronald S.
- Venue
- Science
- Published
- 2012-10-05
- Volume
- 338
- Issue
- 6103
- Pages
- 68-72
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4424898
- OpenAlex
- W2157504436
- Cited by
- 1,651
- References
- 57
- Citations by year
- 2026: 176 · 2025: 175 · 2024: 132 · 2023: 138 · 2022: 127 · 2021: 161 · 2020: 125 · 2019: 86 · 2018: 88 · 2017: 93 · 2016: 89 · 2015: 106 · 2014: 78 · 2013: 71 · 2012: 4
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH093897)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- depression, synaptic dysfunction, synaptogenesis, ketamine, NMDA receptor antagonists, antidepressant resistance, chronic stress, prefrontal cortex, hippocampus, mood regulation, rapid antidepressant response, therapeutic target
- MeSH terms
- Animals, Antidepressive Agents, Atrophy, Behavior, Major Depressive Disorder, Homeostasis, Humans, Neurons, Stress, Psychological, Synapses, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.